USPTO serial 79375534
Serial No. 79375534
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Dec 17, 2024
- Examiner
- EISNACH, MICHAEL PATRICK
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with Serial No. 79375534?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
John Zaccaria
John Zaccaria Notaro, Michalos & Zaccaria P.C.100 Dutch Hill Road, Suite 240Orangeburg, NY 10962United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the central nervous system; pharmaceutical preparations for the treatment of central nervous system (CNS) diseases; pharmaceutical preparations for treating peripheral nervous system disorders; stimulants for the central nervous system; pharmaceutical agents affecting peripheral nervous system; pharmaceutical preparations for the treatment of epilepsy, pharmaceuticals for the treatment of epilepsy and brain health, fever and colds, autoimmune diseases, bacteria-based diseases, bone diseases, cardiovascular and cerebrovascular diseases, central nervous system diseases, diabetes, diseases and disorders of the endocrine system, diseases and disorders of the genitourinary system, diseases and disorders of the musculoskeletal system, eye diseases and conditions, gastrointestinal diseases, gynecological diseases, infectious diseases, inflammatory diseases, insomnia, kidney diseases, metabolic diseases and disorders, neuropathic pain, ocular disorders, pain, respiratory diseases, seizures, sinus congestion, skeletal diseases, skin diseases, and viral diseases, chemico-pharmaceutical preparations for disinfecting and sanitizing, for intimate gynaecological and body hygiene; chemical preparations for pharmaceutical purposes for the treatment of epilepsy and brain health, fever and colds, autoimmune diseases, bacteria-based diseases, bone diseases, cardiovascular and cerebrovascular diseases, central nervous system diseases, diabetes, diseases and disorders of the endocrine system, diseases and disorders of the genitourinary system, diseases and disorders of the musculoskeletal system, eye diseases and conditions, gastrointestinal diseases, gynecological diseases, infectious diseases, inflammatory diseases, insomnia, kidney diseases, metabolic diseases and disorders, neuropathic pain, ocular disorders, pain, respiratory diseases, seizures, sinus congestion, skeletal diseases, skin diseases, and viral diseases; milk ferments for pharmaceutical purposes; decoctions for pharmaceutical purposes for the treatment of epilepsy and brain health, fever and colds, autoimmune diseases, bacteria-based diseases, bone diseases, cardiovascular and cerebrovascular diseases, central nervous system diseases, diabetes, diseases and disorders of the endocrine system, diseases and disorders of the genitourinary system, diseases and disorders of the musculoskeletal system, eye diseases and conditions, gastrointestinal diseases, gynecological diseases, infectious diseases, inflammatory diseases, insomnia, kidney diseases, metabolic diseases and disorders, neuropathic pain, ocular disorders, pain, respiratory diseases, seizures, sinus congestion, skeletal diseases, skin diseases, and viral diseases; digestives for pharmaceutical purposes; ferments for pharmaceutical purposes; lotions for pharmaceutical purposes for the treatment of epilepsy and brain health, fever and colds, autoimmune diseases, bacteria-based diseases, bone diseases, cardiovascular and cerebrovascular diseases, central nervous system diseases, diabetes, diseases and disorders of the endocrine system, diseases and disorders of the genitourinary system, diseases and disorders of the musculoskeletal system, eye diseases and conditions, gastrointestinal diseases, gynecological diseases, infectious diseases, inflammatory diseases, insomnia, kidney diseases, metabolic diseases and disorders, neuropathic pain, ocular disorders, pain, respiratory diseases, seizures, sinus congestion, skeletal diseases, skin diseases, and viral diseases; pastilles for pharmaceutical purposes for the treatment of epilepsy and brain health, fever and colds, autoimmune diseases, bacteria-based diseases, bone diseases, cardiovascular and cerebrovascular diseases, central nervous system diseases, diabetes, diseases and disorders of the endocrine system, diseases and disorders of the genitourinary system, diseases and disorders of the musculoskeletal system, eye diseases and conditions, gastrointestinal diseases, gynecological diseases, infectious diseases, inflammatory diseases, insomnia, kidney diseases, metabolic diseases and disorders, neuropathic pain, ocular disorders, pain, respiratory diseases, seizures, sinus congestion, skeletal diseases, skin diseases, and viral diseases; propolis for pharmaceutical purposes for the treatment of throat and oral cavity conditions; syrups for pharmaceutical purposes for the treatment of epilepsy and brain health, fever and colds, autoimmune diseases, bacteria-based diseases, bone diseases, cardiovascular and cerebrovascular diseases, central nervous system diseases, diabetes, diseases and disorders of the endocrine system, diseases and disorders of the genitourinary system, diseases and disorders of the musculoskeletal system, eye diseases and conditions, gastrointestinal diseases, gynecological diseases, infectious diseases, inflammatory diseases, insomnia, kidney diseases, metabolic diseases and disorders, neuropathic pain, ocular disorders, pain, respiratory diseases, seizures, sinus congestion, skeletal diseases, skin diseases, and viral diseases; ointments for pharmaceutical purposes for the treatment of epilepsy and brain health, fever and colds, autoimmune diseases, bacteria-based diseases, bone diseases, cardiovascular and cerebrovascular diseases, central nervous system diseases, diabetes, diseases and disorders of the endocrine system, diseases and disorders of the genitourinary system, diseases and disorders of the musculoskeletal system, eye diseases and conditions, gastrointestinal diseases, gynecological diseases, infectious diseases, inflammatory diseases, insomnia, kidney diseases, metabolic diseases and disorders, neuropathic pain, ocular disorders, pain, respiratory diseases, seizures, sinus congestion, skeletal diseases, skin diseases, and viral diseases; pharmaceutical preparations for skin care; vitamin supplement patches; dietary supplements with a cosmetic effect; royal jelly dietary supplements; pollen dietary supplements; propolis dietary supplements; nutritional supplements; dietetic foods adapted for medical purposes; analgesics; anaesthetics; antibiotics; anti-inflammatories; antioxidant pills being food supplements; antiseptics; balms for medical purposes; medicated sweets; collyrium; cachets for pharmaceutical purposes for the treatment of epilepsy and brain health, fever and colds, autoimmune diseases, bacteria-based diseases, bone diseases, cardiovascular and cerebrovascular diseases, central nervous system diseases, diabetes, diseases and disorders of the endocrine system, diseases and disorders of the genitourinary system, diseases and disorders of the musculoskeletal system, eye diseases and conditions, gastrointestinal diseases, gynecological diseases, infectious diseases, inflammatory diseases, insomnia, kidney diseases, metabolic diseases and disorders, neuropathic pain, ocular disorders, pain, respiratory diseases, seizures, sinus congestion, skeletal diseases, skin diseases, and viral diseases; adhesive plasters for medical purposes; medicated toothpaste, mineral dietary supplements; medicines for human purposes for the treatment of epilepsy and brain health, fever and colds, autoimmune diseases, bacteria-based diseases, bone diseases, cardiovascular and cerebrovascular diseases, central nervous system diseases, diabetes, diseases and disorders of the endocrine system, diseases and disorders of the genitourinary system, diseases and disorders of the musculoskeletal system, eye diseases and conditions, gastrointestinal diseases, gynecological diseases, infectious diseases, inflammatory diseases, insomnia, kidney diseases, metabolic diseases and disorders, neuropathic pain, ocular disorders, pain, respiratory diseases, seizures, sinus congestion, skeletal diseases, skin diseases, and viral diseases; medicines for dental purposes; medicines for veterinary purposes for the treatment of epilepsy and brain health, autoimmune diseases, bacteria-based diseases, bone diseases, cardiovascular and cerebrovascular diseases, central nervous system diseases, diabetes, diseases and disorders of the endocrine system, diseases and disorders of the genitourinary system, diseases and disorders of the musculoskeletal system, eye diseases and conditions, gastrointestinal diseases, infectious diseases, inflammatory diseases, kidney diseases, metabolic diseases and disorders, neuropathic pain, ocular disorders, pain, respiratory diseases, seizures, skeletal diseases, skin diseases, and viral diseases; chemical preparations for medical purposes for the treatment of epilepsy and brain health, fever and colds, autoimmune diseases, bacteria-based diseases, bone diseases, cardiovascular and cerebrovascular diseases, central nervous system diseases, diabetes, diseases and disorders of the endocrine system, diseases and disorders of the genitourinary system, diseases and disorders of the musculoskeletal system, eye diseases and conditions, gastrointestinal diseases, gynecological diseases, infectious diseases, inflammatory diseases, insomnia, kidney diseases, metabolic diseases and disorders, neuropathic pain, ocular disorders, pain, respiratory diseases, seizures, sinus congestion, skeletal diseases, skin diseases, and viral diseases; chemical preparations for veterinary purposes for the treatment of epilepsy and brain health, autoimmune diseases, bacteria-based diseases, bone diseases, cardiovascular and cerebrovascular diseases, central nervous system diseases, diabetes, diseases and disorders of the endocrine system, diseases and disorders of the genitourinary system, diseases and disorders of the musculoskeletal system, eye diseases and conditions, gastrointestinal diseases, infectious diseases, inflammatory diseases, kidney diseases, metabolic diseases and disorders, neuropathic pain, ocular disorders, pain, respiratory diseases, seizures, skeletal diseases, skin diseases, and viral diseases; nutraceutical preparations for therapeutic or medical purposes for the treatment of epilepsy and brain health, autoimmune diseases, bacteria-based diseases, bone diseases, cardiovascular and cerebrovascular diseases, central nervous system diseases, diabetes, diseases and disorders of the endocrine system, diseases and disorders of the genitourinary system, diseases and disorders of the musculoskeletal system, eye diseases and conditions, gastrointestinal diseases, infectious diseases, inflammatory diseases, kidney diseases, metabolic diseases and disorders, neuropathic pain, ocular disorders, pain, respiratory diseases, seizures, skeletal diseases, skin diseases, and viral diseases; pharmaceutical preparations for the treatment of epilepsy and brain health, autoimmune diseases, bacteria-based diseases, bone diseases, cardiovascular and cerebrovascular diseases, central nervous system diseases, diabetes, diseases and disorders of the endocrine system, diseases and disorders of the genitourinary system, diseases and disorders of the musculoskeletal system, eye diseases and conditions, gastrointestinal diseases, infectious diseases, inflammatory diseases, kidney diseases, metabolic diseases and disorders, neuropathic pain, ocular disorders, pain, respiratory diseases, seizures, skeletal diseases, skin diseases, and viral diseases; mouthwashes for medical purposes; veterinary preparations, namely, veterinary vaccines; purgatives; dietetic substances in the nature of foods, capsules, confectionery, beverages, infusions, syrups, tablets adapted for medical use; suppositories being pharmaceutical preparations for the prevention and/or treatment of epilepsy and brain health, autoimmune diseases, bacteria-based diseases, bone diseases, cardiovascular and cerebrovascular diseases, central nervous system diseases, diabetes, diseases and disorders of the endocrine system, diseases and disorders of the genitourinary system, diseases and disorders of the musculoskeletal system, eye diseases and conditions, gastrointestinal diseases, infectious diseases, inflammatory diseases, kidney diseases, metabolic diseases and disorders, neuropathic pain, ocular disorders, pain, respiratory diseases, seizures, skeletal diseases, skin diseases, and viral diseases; herbal teas for medicinal purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 13, 2025 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| May 24, 2025 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| May 24, 2025 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Mar 17, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jan 17, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jan 1, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 1, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Dec 17, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Dec 17, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 15, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 15, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 25, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 10, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 6, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 6, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 6, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 6, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Sep 6, 2024 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Sep 6, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 6, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Sep 6, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Sep 6, 2024 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Apr 2, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 13, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 13, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Feb 21, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Feb 20, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 12, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 8, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Aug 4, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 3, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |